The SpaceX IPO is dominating financial headlines on June 11, 2026. Pricing at $135 per share and targeting a valuation of approximately $1.8 trillion, it has attracted demand more than four times the available shares — a historic level of investor appetite. While that story plays out, a quieter rotation has been unfolding that is actually putting money in investors’ pockets right now.
Over the five trading days ending June 10, 2026, the healthcare sector rose nearly 6% while the S&P 500 fell approximately 3%. Healthcare outperformed technology stocks over that three-day stretch by the widest margin since 2002, according to data from Bespoke Investment Group. UnitedHealth Group (NYSE: UNH) gained roughly 10% over the past week. Eli Lilly (NYSE: LLY) added approximately 8%. Meanwhile, the Nasdaq fell sharply on fears of SpaceX-related index rebalancing, inflation running at a three-year high of 4.2% annually in May, and stretched tech valuations.
For investors who have been fully concentrated in AI names, what is happening in healthcare right now deserves a closer look.
Why Healthcare Is Moving
The macro setup is favorable in a specific way. When inflation is elevated and market uncertainty is high, investors historically shift toward sectors where demand is non-discretionary. People do not postpone cancer treatments or insulin prescriptions because interest rates are uncertain. UBS analysts noted on June 9, 2026 that healthcare has outperformed the S&P 500 on 85% of days when the benchmark dropped by 1% or more. SentimentTrader analyst Jay Kaeppel flagged the sector’s underperformance year-to-date as a potential catalyst, calling the current environment “an excellent buying opportunity” for healthcare exposure.
The sector had lagged the S&P 500 for most of 2026 while technology dominated. That dynamic appears to be reversing, and the two stocks at the center of the conversation are worth examining individually.
UnitedHealth Group: The Managed Care Giant Finding Its Footing
UnitedHealth Group is the largest health insurer in the United States, operating through two primary segments: UnitedHealthcare, which provides insurance coverage to roughly 52 million members, and Optum, which delivers pharmacy benefits, care delivery, and data analytics services.
On April 21, 2026, the company reported first-quarter results that significantly exceeded expectations. Revenue reached $111.7 billion, up approximately 2% year over year, while adjusted earnings per share came in at $7.23, well above consensus estimates. The standout metric was the medical care ratio — which measures how much of premium revenue the company pays out in claims — improving to 83.9% from 84.8% in the prior year. That improvement signals better cost management and a stabilization in healthcare utilization rates, which had been elevated coming out of the pandemic era.
Multiple analysts raised their price targets in the weeks following that report. JP Morgan’s Lisa Gill boosted her target to $466 on June 8, 2026, and Mizuho’s Ann Hynes raised her target to $460 on the same day. Bank of America upgraded the stock from Neutral to Buy on June 4, 2026, setting a $450 target.
Shares trade at $406.35 as of June 11, 2026, giving UnitedHealth a market cap of approximately $369.0B. The trailing P/E of 30.6x on earnings per share of $13.29 is modest for a company of this scale and consistency. The 52-week range runs from $234.60 to $415.98, meaning the stock is approaching its 52-week high — an unusual setup for a stock that is still considered a defensive holding. All eight tracked analysts carry bullish ratings, with a consensus average price target of $456.25 and the high at $492 from Bernstein.
The primary risk is regulatory pressure on insurer margins, ongoing litigation related to Medicare Advantage reimbursement rates, and the potential cost impact of GLP-1 obesity drugs as they become more widely prescribed across insured populations.
Eli Lilly: The GLP-1 Story Is Bigger Than the Market Thinks
Eli Lilly is not a defensive stock. It is a high-growth pharmaceutical company that happens to benefit from the same rotation into healthcare. The difference between Lilly and UnitedHealth is simple: UnitedHealth is a business you own for stability; Lilly is a business you own for growth.
On April 30, 2026, Lilly reported first-quarter results that exceeded even the most optimistic forecasts. Adjusted EPS of $8.55 beat the Wall Street consensus of $6.66 by nearly 29%. Revenue grew 56% year over year in the quarter, driven by Mounjaro — its GLP-1/GIP injection for Type 2 diabetes — delivering $8.7 billion in sales, more than $1 billion above estimates, and Zepbound — its obesity treatment — contributing $4.2 billion. Management raised full-year 2026 revenue guidance to $82–$85 billion and lifted its adjusted EPS forecast to $35.50–$37.00.
In a May 2026 analysis, Morgan Stanley projected that Lilly’s full GLP-1 franchise could generate $60.3 billion in 2026 worldwide revenue — above the then-current consensus of $55.6 billion — and $70 billion in 2027. The bullish case centers on three things: Mounjaro’s 53% international GLP-1 market share, the April 2026 FDA approval of Foundayo (orforglipron), the first oral GLP-1 pill that can be taken without food or water restrictions, and the addition of Mounjaro to China’s National Reimbursement Drug List effective January 1, 2026.
Shares trade at $1,163.01 as of June 11, 2026, with a market cap of approximately $1.1T. The trailing P/E of 41.3x on earnings per share of $28.15 reflects a premium for a company growing at this pace. The 52-week range is $623.78 to $1,182.73. Jefferies raised its price target to $1,350 on June 9, 2026, and Barclays maintained an Overweight rating with a $1,400 target set on May 5, 2026. The consensus average target is $1,295.14, with the high at $1,400.
The risk is meaningful: GLP-1 pricing pressure from biosimilar competition is expected to emerge in the latter half of this decade, and the company’s near-term revenue is heavily concentrated in two drugs. Any clinical setback or reimbursement reversal would have an outsized impact.
Read Next: Write down this ticker today…
Grab a pen and write down this ticker: TLT.
It could be the single most valuable ticker you hear about all year.
In 2026, billions of dollars could pass through it.
But before you rush out and buy it… WAIT.
There is a very specific way you must play this ticker if you want to make real money from it.
Do it wrong, and you’ll only capture a fraction of what’s possible.
Do it right, and you could double your money in a matter of days.
I know, because I’ve done exactly that before.
My name is Larry Benedict, and I’ve been trading TLT for years.
In that time, I’ve watched a 4% move in this ticker turn into a 117% gain for my readers who followed my recommendation — in just a matter of days.
And it’s all because of the very specific way I trade it.
Discover how to access exactly how I trade this ticker — and why right now is the best setup I’ve seen in years — by watching this exclusive, free briefing.
Click here to learn how to access my complete TLT playbook.
P.S. The current setup on TLT is more attractive than I have seen in years – but it won’t last forever — so if you want to learn how to position for what could be some of your best gains of 2026, click here.
